Cargando…
Clopidogrel: A Pharmacogenomic Perspective on its Use in Coronary Artery Disease
The thienopyridine antiplatelet agent clopidogrel is an effective drug for the prevention of vascular events. However, data has accumulated over time to suggest it is prone to significant interpatient variability. While there are several factors that contribute to this, one of the most important is...
Autor principal: | Terpening, Chris |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998935/ https://www.ncbi.nlm.nih.gov/pubmed/21151850 http://dx.doi.org/10.4137/CMC.S4323 |
Ejemplares similares
-
2220: Pharmacogenomic determinants in Caribbean Hispanics of clopidogrel failure in acute coronary syndrome
por: Melin, Kyle, et al.
Publicado: (2018) -
Pharmacoeconomic Analysis of Clopidogrel in
Secondary Prevention of Coronary Artery Disease
por: Cheng, Judy W.
Publicado: (2007) -
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting
por: Sharma, Rakesh K, et al.
Publicado: (2009) -
Pharmacogenomics in the Management of Pulmonary Arterial Hypertension: Current Perspectives
por: Coons, James C, et al.
Publicado: (2023) -
Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
por: Brown, Sherry-Ann, et al.
Publicado: (2018)